RUNX1 Mutation

CI-VAR-00002640Explore in graph →CIViC 155

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia1
RUNX1 Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID508 In univariate analysis, mutations in RUNX1 were significantly associated with shorter overall survival compared to wildtype RUNX1 in adult (18-87 years old) T-cell acute lymphoblastic leukemia (N=9 mu… (full text at CIViC) PMID 23341344 · Grossmann et al., 2013 · Open in CIViC	civic
Acute Myeloid Leukemia5
RUNX1 Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID429 In 878 non-APL patients with AML, those who had mutations in RUNX1 (N=53) had higher rates of refractory disease than those without (30% versus 19%; P = 0.047). PMID 21343560 · Gaidzik et al., 2011 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Myelodysplastic Syndrome1
RUNX1 Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID6944 In a study of 439 patients with myelodysplastic syndrome, patients with RUNX1 mutations (N=38) has worse overall survival than wildtype patients (N=401) (P<0.001 univariate). This difference was also … (full text at CIViC) PMID 21714648 · Bejar et al., 2011 · Open in CIViC	civic